Alpha-gal nanoparticles
Alpha-gal nanoparticles has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Mar 17, 2026: “The α-Gal Epitope (Galα1-3Galβ1-4GlcNAc) as Therapeutic Agent in Cancer Immunotherapy, Vaccine Effectiveness Amplification and Injured Tissue Regeneration”.
2 papers study it2 findingsUpdated
See all 2 papers on alpha-gal nanoparticles
What did studies of alpha-gal nanoparticles find?
2Studies of alpha-gal nanoparticles measured 2 outcomes: complement system and injured myocardium regeneration.
Complement system
upin humans1
1 study
Complement system
upin humans1
Alpha-gal nanoparticles activate complement system in injured tissue.
“Anti-Gal binding to α-gal-presenting nanoparticles administered to wounds, into the post-myocardial infarction (MI) injured myocardium and into injured spinal cord, activates the complement system”
Reviewin injured tissue
International journal of molecular sciences
Injured myocardium regeneration
upin mice1
1 study
Injured myocardium regeneration
upin mice1
Alpha-gal nanoparticles improve injured myocardium regeneration in mice (post-MI in anti-Gal-producing mice).
“This process results in near-complete regeneration of the injured myocardium within 14 days.”
Reviewpost-MI in anti-Gal-producing micemyocardium14 days
International journal of molecular sciences